2型糖尿病药物治疗的未来方向
本文为叙述性综述,探讨处于早期开发阶段的非胰岛素类降糖药物及治疗策略,旨在改善2型糖尿病血糖控制。理想疗法应通过现有机制或靶向不同病理生理环节降糖,避免低血糖、便于体重管理、使用方便、不良反应少、对常见共病有益且安全性良好。最有前景的是基于肠促胰素的共激动剂和多激动剂及基于胰淀素的合成肽,初步研究提示可改善胰岛素分泌、辅助胰岛β细胞保护、增强胰岛素介导的糖代谢,同时减少胰高血糖素分泌和脂肪肝风险。
要点
- 肠促胰素类共激动剂/多激动剂及胰淀素类合成肽是未来最有前景的非胰岛素降糖疗法。
- 初步研究提示上述疗法可改善胰岛素分泌、辅助β细胞保护并减少胰高血糖素分泌。
- 多组学、miRNA、基因编辑和表观遗传靶点尚未产出可用疗法。
核心结论
- 肠促胰素类共激动剂/多激动剂及胰淀素类合成肽是未来2型糖尿病非胰岛素治疗中最有前景的方向。
- 近期减重肠促胰素类药物的成功提升了药物管线变革2型糖尿病管理的预期。
研究设计与样本
- 叙述性综述,聚焦2型糖尿病未来非胰岛素药物及早期开发中的治疗策略。
主要发现
- 初步研究提示肠促胰素类共激动剂/多激动剂及胰淀素类合成肽可改善胰岛素分泌、辅助胰岛β细胞保护、增强胰岛素介导的糖代谢,并减少胰高血糖素分泌和脂肪肝风险。
- 与肠促胰素靶点相互作用的抗体和小分子、调节线粒体功能、脂肪酸受体及影响食欲或营养代谢通路的胃肠道和脂肪细胞肽受体的药物正在开发中。
- 多组学、miRNA、基因编辑技术和表观遗传靶点受到关注但尚未产出可用疗法。
- 将治疗药物导向特定器官或组织并避免脱靶效应,仍是实验室创新转化为可行临床药物的挑战。
临床怎么用
- 关注肠促胰素类共激动剂/多激动剂及胰淀素类合成肽的临床研究进展,其可能同时改善血糖和体重。
局限性
- 叙述性综述,未提供系统检索策略或定量证据汇总。
- 多数提及的疗法处于早期开发阶段,尚未转化为可用临床药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the availability of at least nine differently acting classes of glucose-lowering agents, many people with type 2 diabetes do not achieve or maintain sufficiently tight glycaemic control to avoid the complications of chronic hyperglycaemia. This narrative review examines the prospects for future non-insulin agents and therapeutic approaches in early development that aim to improve glycaemic control in type 2 diabetes. Such therapies will ideally enhance glucose lowering through existing mechanisms or by targeting different aspects of disease pathophysiology. They will avoid overt hypoglycaemia and facilitate weight control and be convenient to use, have minimal adverse effects, provide benefits against common comorbidities and have a commendable overall safety profile. Particularly promising therapies in development are the co-agonist and multi-agonist incretin-based and amylin-based synthetic peptides that improve glycaemic control and body weight regulation. Initial studies suggest that such therapies can improve insulin secretion, assist pancreatic beta cell preservation and enhance insulin-mediated glucose metabolism while reducing glucagon secretion and risk of fatty liver disease. Antibodies and small molecules that interact with incretin targets are also being developed, as well as agents to modulate mitochondrial function, fatty acid receptors and receptors for selected gastrointestinal and adipocyte peptides that affect appetite or pathways of nutrient metabolism. Multiomics, miRNAs, gene-editing technologies and epigenetic targets have received considerable attention but have yet to deliver usable therapies. Directing therapeutic agents to specific organs or tissues and avoiding unwanted off-target effects continue to challenge the application of laboratory innovations into viable clinical agents. However, recent successes with weight-lowering incretin-based medicines have raised expectations for pharmaceutical pipelines to transform the management of type 2 diabetes.
引用
- Bailey CJ. Pharmacological therapies for type 2 diabetes: future approaches. Diabetologia. 2025. PMID: 41174263. doi:10.1007/s00125-025-06581-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。